Go with the (cash) flow

Investment and infrastructure have been put in place to rapidly translate ATMPs from concept to clinic. But are we doing enough?


SALLY ANN FORSYTH | Chief Executive Officer | Stevenage Bioscience Catalyst


DAN PEARCE | Vice President, European Manufacturing & Technical Operations | Adaptimmune
WILL ROHLEDER | Director | Reef Group
KASIA AVERALL | Head of Cluster Development | Cell and Gene Therapy Catapult
JENNY LAIRD | Vice President, Search & Evaluation Pain & Neurodegeneration |  Eli Lilly and Company
MARY JONES | Deputy Director for Strategy, Investment and Manufacturing | Office for Life Sciences